SKYE vs. ATYR, CGEM, KMDA, ORKA, MREO, PGEN, PRTC, RGNX, RAPP, and TRML
Should you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include aTyr Pharma (ATYR), Cullinan Therapeutics (CGEM), Kamada (KMDA), Oruka Therapeutics (ORKA), Mereo BioPharma Group (MREO), Precigen (PGEN), PureTech Health (PRTC), REGENXBIO (RGNX), Rapport Therapeutics (RAPP), and Tourmaline Bio (TRML). These companies are all part of the "pharmaceutical products" industry.
Skye Bioscience vs. Its Competitors
aTyr Pharma (NASDAQ:ATYR) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.
In the previous week, aTyr Pharma had 2 more articles in the media than Skye Bioscience. MarketBeat recorded 3 mentions for aTyr Pharma and 1 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 1.02 beat aTyr Pharma's score of 0.66 indicating that Skye Bioscience is being referred to more favorably in the news media.
Skye Bioscience has lower revenue, but higher earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.
aTyr Pharma presently has a consensus target price of $20.20, suggesting a potential upside of 284.47%. Skye Bioscience has a consensus target price of $16.60, suggesting a potential upside of 262.84%. Given aTyr Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe aTyr Pharma is more favorable than Skye Bioscience.
61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 3.7% of aTyr Pharma shares are held by insiders. Comparatively, 4.5% of Skye Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Skye Bioscience's return on equity of -53.92% beat aTyr Pharma's return on equity.
aTyr Pharma has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500.
Summary
aTyr Pharma and Skye Bioscience tied by winning 7 of the 14 factors compared between the two stocks.
Get Skye Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skye Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:SKYE) was last updated on 7/5/2025 by MarketBeat.com Staff
